Resumes
Resumes
Wattanaporn Abramowitz Phones & Addresses
-
Princeton Junction, NJ
-
45 Blanchard Ave, Dobbs Ferry, NY 10522 (914) 246-3497
-
Somerset, NJ
-
Corvallis, OR
-
Cranbury, NJ
Publications
Us Patents
Method Of Treating Acute Pain With A Unitary Dosage Form Comprising Ibuprofin And Oxycodone
View pageUS Patent:
20040186122, Sep 23, 2004
Filed:
Dec 1, 2003
Appl. No.:
10/725246
Inventors:
Kenneth Newman - Katonah NY, US
Wattanaporn Abramowitz - West Windsor NJ, US
Andreas Grill - Hauppauge NY, US
Pablo Davila-Zavala - East Windsor NJ, US
Fuxing Tang - Deer Park NY, US
Wattanaporn Abramowitz - West Windsor NJ, US
Andreas Grill - Hauppauge NY, US
Pablo Davila-Zavala - East Windsor NJ, US
Fuxing Tang - Deer Park NY, US
Assignee:
Forest Laboratories, Inc.
International Classification:
A61K031/485
A61K031/192
A61K031/192
US Classification:
514/282000, 514/570000
Abstract:
The present invention is a method of achieving fast onset of pain relief for acute pain in a patient in need thereof comprising orally administering a unitary formulation (or oral dosage form) containing an effective analgesic amount of (a) oxycodone or a pharmaceutically acceptable salt thereof and (b) ibuprofen or a pharmaceutically acceptable salt thereof. Preferably, the unitary formulation contains (a) oxycodone or a pharmaceutically acceptable salt thereof and (b) ibuprofen or a pharmaceutically acceptable salt thereof at a weight ratio of from about 1:20 to about 1:100 and more preferably about 1:40 to about 1:80, based on the weights of molar equivalents of oxycodone hydrochloride and ibuprofen, respectively. Preferably, an amount of oxycodone and ibuprofen effective to provide partial or complete pain relief within 30 minutes is administered. More preferably, the amount is sufficient to provide partial or complete pain relief within 25 minutes. It has been discovered that administration of an oral dosage form containing both oxycodone and ibuprofen provides earlier onset of pain relief than administration of either active ingredient alone. Moreover, the earlier onset of pain relief may be attributable at least in part to administration of a single dosage form containing both active ingredients as opposed to administering oxycodone and ibuprofen in separate oral dosage forms (i.e., administration of a first dosage form containing oxycodone and a second dosage form containing ibuprofen). The method of the present invention is particularly useful for treating acute postoperative pain, including, but not limited to, moderate and/or severe acute postoperative pain (such as that resulting from dental surgery).
Method Of Treating Acute Pain With Unitary Dosage Form Comprising Ibuprofen And Oxycodone
View pageUS Patent:
20050038063, Feb 17, 2005
Filed:
Jun 2, 2004
Appl. No.:
10/861239
Inventors:
Kenneth Newman - Katonah NY, US
Wattanaporn Abramowitz - West Windsor NJ, US
Andreas Grill - Hauppauge NY, US
Pablo Davila-Zavala - East Windsor NJ, US
Fuxing Tang - Deer Park NY, US
Wattanaporn Abramowitz - West Windsor NJ, US
Andreas Grill - Hauppauge NY, US
Pablo Davila-Zavala - East Windsor NJ, US
Fuxing Tang - Deer Park NY, US
International Classification:
A61K031/485
A61K031/192
G06F017/60
A61K031/192
G06F017/60
US Classification:
514282000, 514570000, 705002000
Abstract:
The present invention is a method of achieving fast onset of pain relief for acute pain in a patient in need thereof comprising orally administering a unitary formulation (or oral dosage form) containing an effective analgesic amount of (a) oxycodone or a pharmaceutically acceptable salt thereof and (b) ibuprofen or a pharmaceutically acceptable salt thereof. Preferably, the unitary formulation contains (a) oxycodone or a pharmaceutically acceptable salt thereof and (b) ibuprofen or a pharmaceutically acceptable salt thereof at a weight ratio of from about 1:20 to about 1:100 and more preferably about 1:40 to about 1:80, based on the weights of molar equivalents of oxycodone hydrochloride and ibuprofen, respectively. Preferably, an amount of oxycodone and ibuprofen effective to provide partial or complete pain relief within 30 minutes is administered. More preferably, the amount is sufficient to provide partial or complete pain relief within 25 minutes. It has been discovered that administration of an oral dosage form containing both oxycodone and ibuprofen provides earlier onset of pain relief than administration of either active ingredient alone. Moreover, the earlier onset of pain relief may be attributable at least in part to administration of a single dosage form containing both active ingredients as opposed to administering oxycodone and ibuprofen in separate oral dosage forms (i.e., administration of a first dosage form containing oxycodone and a second dosage form containing ibuprofen). The method of the present invention is particularly useful for treating acute postoperative pain, including, but not limited to, moderate and/or severe acute postoperative pain (such as that resulting from dental surgery).
Method Of Treating Acute Pain With A Unitary Dosage Form Comprising Ibuprofen And Oxycodone
View pageUS Patent:
20050059690, Mar 17, 2005
Filed:
Aug 23, 2004
Appl. No.:
10/925783
Inventors:
Kenneth Newman - Kotonah NY, US
Wattanaporn Abramowitz - West Windsor NJ, US
Andreas Grill - Hauppauge NY, US
Pablo Davila-Zavala - East Windsor NJ, US
Fuxing Tang - Deer Park NY, US
Wattanaporn Abramowitz - West Windsor NJ, US
Andreas Grill - Hauppauge NY, US
Pablo Davila-Zavala - East Windsor NJ, US
Fuxing Tang - Deer Park NY, US
Assignee:
Forest Laboratories, Inc. - New York NY
International Classification:
A61K031/485
A61K031/192
A61K031/192
US Classification:
514282000, 514570000
Abstract:
The present invention is a method of achieving fast onset of pain relief for acute pain in a patient in need thereof comprising orally administering a unitary formulation (or oral dosage form) containing an effective analgesic amount of (a) oxycodone or a pharmaceutically acceptable salt thereof and (b) ibuprofen or a pharmaceutically acceptable salt thereof. Preferably, the unitary formulation contains (a) oxycodone or a pharmaceutically acceptable salt thereof and (b) ibuprofen or a pharmaceutically acceptable salt thereof at a weight ratio of from about 1:20 to about 1:100 and more preferably about 1:40 to about 1:80, based on the weights of molar equivalents of oxycodone hydrochloride and ibuprofen, respectively. Preferably, an amount of oxycodone and ibuprofen effective to provide partial or complete pain relief within 30 minutes is administered. More preferably, the amount is sufficient to provide partial or complete pain relief within 25 minutes. It has been discovered that administration of an oral dosage form containing both oxycodone and ibuprofen provides earlier onset of pain relief than administration of either active ingredient alone. Moreover, the earlier onset of pain relief may be attributable at least in part to administration of a single dosage form containing both active ingredients as opposed to administering oxycodone and ibuprofen in separate oral dosage forms (i.e., administration of a first dosage form containing oxycodone and a second dosage form containing ibuprofen). The method of the present invention is particularly useful for treating acute postoperative pain, including, but not limited to, moderate and/or severe acute postoperative pain (such as that resulting from dental surgery).
Immediate Release Formulations Of 1-Aminocyclohexane Compounds, Memantine And Neramexane
View pageUS Patent:
20060002999, Jan 5, 2006
Filed:
Jun 16, 2005
Appl. No.:
11/155319
Inventors:
Yan Yang - Roslyn Heights NY, US
Rajiv Janjikhel - South Setauket NY, US
Niranjan Rao - Belle Mead NY, US
Antonia Periclou - Jersey City NJ, US
Wattanaporn Abramowitz - Hillsborough NJ, US
Mahendra Dedhiya - Pomona NY, US
Erhard Seiller - Nidderau, DE
Bernhard Hauptmeier - Gelnhausen, DE
Rajiv Janjikhel - South Setauket NY, US
Niranjan Rao - Belle Mead NY, US
Antonia Periclou - Jersey City NJ, US
Wattanaporn Abramowitz - Hillsborough NJ, US
Mahendra Dedhiya - Pomona NY, US
Erhard Seiller - Nidderau, DE
Bernhard Hauptmeier - Gelnhausen, DE
Assignee:
Forest Laboratories, Inc. - New York NY
International Classification:
A61K 9/20
A61K 31/13
A61K 31/13
US Classification:
424464000, 514662000
Abstract:
The present invention relates to an immediate release solid oral dosage form containing 1-aminocyclohexanes, preferably memantine or neramexane, and optionally a pharmaceutically acceptable coating, wherein the active ingredient exhibits dose proportionality and is released at a dissolution rate of more than about 80% within about the first 60 minutes following entry of said form into a use environment. The dosage form is direct compressed and has a hardness within the range of between about 3 and about 40 Kp, exhibits an average Twithin the range of about 2 to about 8 hours with an active ingredient load within the range of about 2.5 to about 150 mg. The formulation allows for dose-proportional compositions for once daily or b.i.d. dosing, while maintaining a steady average range of T.
Modified Release Formulations Of Memantine Oral Dosage Forms
View pageUS Patent:
20060051416, Mar 9, 2006
Filed:
Jun 16, 2005
Appl. No.:
11/155330
Inventors:
Suneel Rastogi - Island Park NY, US
Niranjan Rao - Belle Mead NJ, US
Antonia Periclou - Jersey City NJ, US
Wattanaporn Abramowitz - Hillsborough NJ, US
Mahendra Dedhiya - Pomona NY, US
Shashank Mahashabde - Kendall Park NJ, US
Niranjan Rao - Belle Mead NJ, US
Antonia Periclou - Jersey City NJ, US
Wattanaporn Abramowitz - Hillsborough NJ, US
Mahendra Dedhiya - Pomona NY, US
Shashank Mahashabde - Kendall Park NJ, US
Assignee:
Forest Laboratories, Inc. - New York NY
International Classification:
A61K 9/22
A61K 31/13
A61K 31/13
US Classification:
424468000, 514662000
Abstract:
The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.
Lercanidipine Ph Dependent Pulsatile Release Compositions
View pageUS Patent:
20060165788, Jul 27, 2006
Filed:
Sep 9, 2005
Appl. No.:
11/223491
Inventors:
Wattanaporn Abramowitz - West Windsor NJ, US
Ram Kapil - Princeton Junction NJ, US
Todd Riccobene - Basking Ridge NJ, US
Mahendra Dedhiya - Pomona NY, US
Suneel Rastogi - Ballwin MO, US
Anil Chhettry - Holtsville NY, US
Ram Kapil - Princeton Junction NJ, US
Todd Riccobene - Basking Ridge NJ, US
Mahendra Dedhiya - Pomona NY, US
Suneel Rastogi - Ballwin MO, US
Anil Chhettry - Holtsville NY, US
International Classification:
A61K 31/445
A61K 9/22
A61K 9/22
US Classification:
424468000, 514317000
Abstract:
Pursuant to the present invention it has been found that a modified release composition containing the low solubility and permeability drug, lercanidipine may be prepared that provides for therapeutically effective plasma concentrations of lercanidipine for 24 hours. The modified release composition of the present invention release pulses of lercanidipine based on the pH of the use environment. An effective quantity of dissolved lercanidipine is released throughout the GI Tract.
Lercanidipine Modified Release Compositions
View pageUS Patent:
20060165789, Jul 27, 2006
Filed:
Sep 9, 2005
Appl. No.:
11/223493
Inventors:
Wattanaporn Abramowitz - West Windsor NJ, US
Ram Kapil - Princeton Junction NJ, US
Todd Riccobene - Basking Ridge NJ, US
Mahendra Dedhiya - Pomona NY, US
Yan Yang - Roslyn Heights NY, US
Anil Chhettry - Holtsville NY, US
Ram Kapil - Princeton Junction NJ, US
Todd Riccobene - Basking Ridge NJ, US
Mahendra Dedhiya - Pomona NY, US
Yan Yang - Roslyn Heights NY, US
Anil Chhettry - Holtsville NY, US
Assignee:
Forest Laboratories, Inc. - New York NY
International Classification:
A61K 31/445
A61K 9/22
A61K 9/22
US Classification:
424468000, 514317000
Abstract:
Pursuant to the present invention, it has been found that a modified release composition containing the low permeability and poor solubility drug, lercanidipine, may be prepared which provides for therapeutically effective plasma concentrations of lercanidipine for a period of about 20 to about 25 hours. The modified release composition of the present invention provides modified release of lercanidipine independent of pH and therefore provides release of lercanidipine even upon exposure to the low pH use environments, such as gastric fluid.
Immediate Release Formulations Of 1-Aminocyclohexane Compounds, Memantine And Neramexane
View pageUS Patent:
20060198884, Sep 7, 2006
Filed:
Dec 14, 2005
Appl. No.:
11/304976
Inventors:
Yan Yang - Roslyn Heights NY, US
Rajiv Janjikhel - Bridgewater NY, US
Niranjan Rao - Belle Mead NJ, US
Antonia Periclou - Jersey City NJ, US
Wattanaporn Abramowitz - West Windsor NJ, US
Mahendra Dedhiya - Pomona NY, US
Erhard Seiller - Nidderau, DE
Bernhard Hauptmeier - Gelnhausen, DE
Rajiv Janjikhel - Bridgewater NY, US
Niranjan Rao - Belle Mead NJ, US
Antonia Periclou - Jersey City NJ, US
Wattanaporn Abramowitz - West Windsor NJ, US
Mahendra Dedhiya - Pomona NY, US
Erhard Seiller - Nidderau, DE
Bernhard Hauptmeier - Gelnhausen, DE
Assignee:
Forest Laboratories, Inc. - New York NY
International Classification:
A61K 31/13
A61K 9/20
A61K 9/20
US Classification:
424464000, 514663000
Abstract:
The present invention relates to an immediate release solid oral dosage form containing 1-aminocyclohexanes, preferably memantine or neramexane, and optionally a pharmaceutically acceptable coating, wherein the active ingredient exhibits dose proportionality and is released at a dissolution rate of more than about 80% within about the first 60 minutes following entry of said form into a use environment. The dosage form is direct compressed and has a hardness within the range of between about 3 and about 40 Kp, exhibits an average Twithin the range of about 2 to about 8 hours with an active ingredient load within the range of about 2.5 to about 150 mg. The formulation allows for dose-proportional compositions for once daily or b.i.d. dosing, while maintaining a steady average range of T.